



Commercial/Healthcare Exchange PA Criteria Effective: January 1, 2021

Prior Authorization: Cinacalcet

Products Affected: cinacalcet 30mg, 60mg, 90mg oral tablets

Medication Description:

Cinacalcet is a calcium-sensing receptor agonist (calcimimetic) indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis.¹ It is also indicated for the treatment of hypercalcemia in adult patients with parathyroid carcinoma and for the treatment of hypercalcemia in adult patients with primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy.

Covered Uses:

1. Hypercalcemia due to Parathyroid Carcinoma
2. Hypercalcemia in Patients with Primary Hyperparathyroidism
3. Secondary Hyperparathyroidism

Exclusion Criteria:

1. Patients with serum calcium less than the lower limit of the normal range

Required Medical Information:

1. Diagnosis

Age Restrictions: 18 years of age and older

Prescriber Restrictions: Prescribed by, or in consultation with, an oncologist, nephrologist, or endocrinologist.

Coverage Duration: Initial and Continuation: 12 months

Other Criteria:

Initial

Hypercalcemia due to Parathyroid Carcinoma

- A. Patient has a diagnosis of hypercalcemia with parathyroid carcinoma.

Hypercalcemia in Patients with Primary Hyperparathyroidism

- A. Patient has a diagnosis of hypercalcemia with primary hyperparathyroidism; **AND**
- B. Patient has failed or is unable to undergo parathyroidectomy due to a contraindication.

Secondary Hyperparathyroidism

- A. Patient has a diagnosis of secondary hyperparathyroidism with chronic kidney disease; **AND**
- B. Patient is on dialysis; **AND**

January 2021



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

Page 1 of 2



- C. Patient has a documented intolerance to, contraindication, or treatment failure with one phosphate binder (e.g. sevelamer carbonate); **AND**
- D. Patient has a documented intolerance to, contraindication, or treatment failure with one vitamin D analog (e.g. calcitriol)

Continuation

- A. Patient has stabilization of serum calcium levels.

References:

- 1. Sensipar [prescribing information]. Thousand Oaks, CA: Amgen Inc.; December 2019.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	1/1/2021